CAR-T-cell therapies

Vreugdenburg T, Moshi MR, Min M, Nicolopoulos K, Stringer D
Record ID 32018005506
English
Original Title: The CAR T cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B cell acute lymphoblastic leukaemia, diffuse large B cell lymphoma and primary mediastinal B cell lymphoma
Details
Project Status: Ongoing
Anticipated Publish Date: 2024
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Switzerland
MeSH Terms
  • Leukemia, B-Cell
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Receptors, Chimeric Antigen
  • Immunotherapy, Adoptive
  • Antineoplastic Agents, Immunological
Keywords
  • CAR T cell therapies
  • CAR-T
  • tisagenlecleucel
  • Yescarta®
  • Kymriah®
  • diffuse large B cell lymphoma
  • lymphoma
  • B cell acute lymphocytic leukaemia
  • leukaemia
  • primary mediastinal B cell lymphoma
  • axicabtagene ciloleucel
  • PROMs
  • efficacy
  • effectiveness
  • safety
  • costs
  • economics
  • cost-effectiveness
  • budget impact
  • legal
  • social
  • ethical
  • organisational
Contact
Organisation Name: Swiss Federal Office of Public Health (FOPH)
Contact Address: Federal Office of Public Health, Schwarzenburgstrasse 157, CH-3003 Berne, Switzerland
Contact Name: Stephanie Vollenweider
Contact Email: hta@bag.admin.ch
Copyright: Swiss Federal Office of Public Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.